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Abstract
Background. Acromegaly is a rare and serious syndrome that is commonly associated with pituitary neo-
plasms. Thyroid multinodular disease is a common finding in acromegaly. Leptin is a polypeptide hormone, 
and studies have shown that it can increase cell proliferation and inhibit apoptosis.
Objectives. The aim of the study was to determine the relationship of serum leptin levels with certain 
blood parameters and determine if growth hormone receptor (GHR)-d3/fl gene polymorphism is associ-
ated with thyroid nodules in acromegalic patients.
Material and methods. A total of 24 acromegalic patients with or without thyroid nodules were included 
in the study. Gene polymorphisms and blood parameters were examined.
Results. A marked increase was observed in serum leptin concentration in acromegalic patients with thy-
roid nodules compared to patients without them (p < 0.05). GH levels were lower in patients without 
nodules than in patients with nodules (p < 0.05). Blood glucose levels were higher in patients with nodules 
compared to those without them (p < 0.05), and the presence of thyroid nodules was associated with 
decreased blood low-density lipoprotein (LDL) levels compared to patients without nodules (p < 0.05). 
A significant relationship was observed between growth hormone receptor (GHR)-d3/fl gene polymor-
phism and leptin levels in acromegalic patients with thyroid nodules (p < 0.001).
Conclusions. These data from acromegalic patients indicate that thyroid nodules are associated with in-
creased serum leptin, GH and blood glucose levels and with decreased LDL levels. GHR-d3/fl gene polymor-
phism status was strongly related to higher leptin levels.
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Acromegaly is associated with excessive secretion of 
growth hormone (GH) and insulin-like growth factor-1 
(IGF-1), resulting in bone overgrowth and an increase in 
soft tissue.1 Thyroid nodules are a common clinical prob-
lem in females. Epidemiological studies have shown the 
prevalence of palpable thyroid nodules to be approximately 
5% in women and 1% in men living in iodine-sufficient 
parts of the world.2,3 In  contrast, high-resolution ultra-
sound can detect thyroid nodules in 19–67% of randomly 
selected individuals, with higher frequencies in women and 
the elderly.4 Thyroid enlargement can also be seen in acro-
megalic patients.5,6 Long-term elevation of serum GH levels 
in acromegaly is associated with goiter development and is 
probably caused by the mitogenic effects of IGF-1.7
Changes in enzyme activity may lead to somewhat 
higher serum triiodothyronine (T3) and lower reverse T3 
(rT3) concentrations in patients with active acromegaly, 
although the levels are usually within physiological rang-
es.8,9 The  prevalence rates of certain benign and malig-
nant neoplasms are higher in acromegalic patients com-
pared with the healthy population.10
Leptin is a potent anorexigenic hormone found in the 
anterior pituitary and secreted by adipose tissue in pro-
portion to adipose content. It is a product of the obesity 
(Ob) gene that regulates both satiety and energy expen-
diture.11 Leptin is secreted with diurnal fluctuations, and 
greater secretion is observed in subjects who are obese 
or who have insulin resistance.12,13 While a negative influ-
ence of thyroid hormones on serum leptin concentrations 
has been described, some authors report no influence of 
thyroid hormones on leptin levels.14–17
There are many reports concerning the stimulatory ef-
fect of leptin on cell mitosis and its involvement in the 
carcinogenesis of breast, colon, prostate, lung, kidney and 
ovary cells. Studies have shown that leptin’s abilities to in-
crease cell proliferation and inhibit apoptosis are involved 
in creating certain types of tumors.18–24 Specifically, in-
creased expression of leptin and its receptor are well docu-
mented in papillary thyroid cancer. Similar to other tumor 
types, some authors reported that leptin exerts oncogenic 
effects on papillary thyroid carcinoma cells by stimulating 
cell proliferation and inhibiting apoptosis.25–27
The principal regulator of GH sensitivity is the GH re-
ceptor (GHR) and consists of an extracellular domain of 
246 amino acids, a  single transmembrane domain, and 
a  cytoplasmic domain. The  encoding gene has 9 exons, 
but there are 2 isoforms of the GHR in humans generated 
by the deletion of exon 3 of the gene, resulting in 3 geno-
types: homozygous GHR-fl, homozygous GHR-d3, and 
heterozygous GHR-d3/fl.28
Objectives
Acromegaly is frequently associated with thyroid en-
largement, and the size is dependent on the duration of 
GH excess.5,6 Thyroid multinodular disease is a common 
finding in acromegaly.5,7,29,30 The reported frequencies of 
diffuse goiter and nodular goiter in acromegalic patients 
are 78–92 and 63%, respectively.5 Leptin, an Ob gene 
product, is secreted exclusively by adipocytes and regu-
lates energy balance. Because GH modulates fat mass, it 
is possible that GH and chronic GH excess affects leptin. 
The aim of this study was to examine leptin levels in acro-
megalic patients, with or without thyroid nodules, and to 
identify any relationship with GHR gene polymorphism.
Material and methods
Study design
The  study was performed according to the Helsinki 
Declaration and was approved by the Ethical Commit-
tee of Pamukkale University (09/198). All the patients 
and volunteers provided written acknowledgement of 
informed consent for participation. The study group in-
cluded 24 patients with acromegaly (13 males, 11 females; 
mean age, 52.04  ±  standard deviation [SD] 9.46; range, 
30–68  years), including 17  patients with thyroid nod-
ules (9 males and 8 females; mean age, 51.05 ± SD 9.66; 
range, 19–84 years) and 7 patients without thyroid nod-
ules (4 males, 3 females; mean age, 46 ± SD 17.6; range, 
30–68 years). The participants’ anthropometric measure-
ments and blood parameters were evaluated.
The diagnosis of acromegaly was established on the ba-
sis of criteria proposed by Freda and confirmed by patho-
logical examination of surgically resected tissues31. Clini-
cal signs, magnetic resonance imaging (MRI), and GH 
and IGF-1 levels were assessed to support the diagnosis. 
Active acromegaly was associated with increased serum 
levels of GH and IGF-1, and modified sellar morphology 
visible on MRI, indicating the presence of a pituitary ad-
enoma.
The main inclusion criteria were age over 18 years and 
the presence of acromegaly.
The patients included in the study were not surgically 
or medically treated for acromegaly (e.g. with somatosta-
tin, dopamine analogs or GH receptor antagonists) at the 
time of inclusion in the study. Exclusion criteria included 
pregnancy, the use of any drugs at the time of the study 
or current surgical treatment for thyroid nodules. On this 
basis 11 patients were excluded from the study.
Clinical and laboratory assessment
Height and weight were measured in light clothing 
without shoes. Body height and weight were measured 
by a statometer and digital electronic scale, respectively. 
Body mass index (BMI) was calculated as the patient’s 
weight in kilograms divided by the square of his/her 
height in meters. The  average value of systolic and dia-
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stolic blood pressure measurements were taken with the 
subject in a sitting position at 2- to 3-min intervals after 
resting for at least 15 min.
Serum levels of glucose, total cholesterol, triglycer-
ide, high- and low-density lipoprotein (HDL and LDL) 
cholesterol, alkaline phosphatase (ALP), calcium and 
phosphorus were analyzed with commercial kits (Beck-
man-Coulter Inc., Brea, USA) in an LX-20 autoanalyzer 
(Beckman-Coulter Inc., Brea, USA). Levels of serum in-
sulin, free T3, free thyroxine (T4), thyroid-stimulating 
hormone, prolactin, GH, leptin, IGF-1 and insulin-like 
growth factor-binding protein 3 (IGFB3) were measured 
in an Immulite 2000 immunoassay analyzer (Siemens 
Healthcare, Erlangen, Germany) using the chemilumines-
cence method.
Genetic analysis
DNA was isolated from peripheral blood with a  stan-
dard phenol/chloroform extraction method. Genotyping 
for the d3 gene was performed by the polymerase chain 
reaction (PCR) method using a  personal thermal cycler 
(Techgene, USA). PCR was conducted in 50 μL reaction 
mixture containing about 1 μg of DNA sample, 5 μL re-
action buffer (x10) include 160 mM (NH4)2SO4, 670 mM 
Tris-HCl (pH 8.8), 0.1% Tween-20, 5 μL dNTP (2 mM), 
3 μL MgCl2 (25 mM), 1 U platinum Taq-polymerase and 
100 pmol of each primer. The following primers were used: 
G1 5’-TGT GCT GGT CTG TTG GTC TG-3’, G2 5’-AGT 
CGT TCC TGG GAC AGA GA-3’ and G3 5’-CCT GGA 
TTA ACA  CTT TGC AGA  CTC-3’ (32). Amplification 
was performed for 39 cycles comprised of denaturation, 
extension and annealing at temperatures of 94°C for 30 s, 
57°C for 30 s, and 68°C for 30 s, respectively. The final ex-
tension time was carried out at 68°C for 10 min. The ini-
tial denaturation stage was carried out at 95°C for 2 min. 
The  fragments obtained were electrophoresed in a  1% 
agarose gel and visualized by ethidium bromide staining 
under ultraviolet (UV) light. The polymorphism detected 
by PCR was evident as a 935-bp fragment in the presence 
of the full-length (fl/fl) fragment and as a 592-bp product 
in the presence of the deletion (d3/d3). Each sample was 
described as d3/d3, d3/fl, or fl/fl.
Statistical analysis
Descriptive statistics, proportions for categorical vari-
ables, and means and SDs for continuous variables were 
used to describe the study groups. Comparisons between 
acromegalic patients with and without thyroid nod-
ules were made with Student’s t-tests. The  results were 
expressed as means  ±  standard error. Mann-Whitney 
U tests were performed to analyze between-group differ-
ences in continuous variables. Values were considered to 
be statistically significant when p < 0.05. Comparisons of 
gene polymorphisms and leptin levels were made by one-
way analysis of variance (ANOVA). Regression analysis 
was used to tease out the impact of the genotype. All sta-
tistical analyses were carried out using SPSS 10.0 software 
(SPSS Inc., Chicago, USA).
Results
A  total of 24 acromegalic patients were included: 
13 males (9 with nodules and 4 without) and 11 females 
(8 with nodules and 3 without). The  mean ages of the 
participants with and without nodules were 51.05 ± 9.66 
and 54.57 ± 9.18, respectively (p > 0.05). The participants’ 
anthropometric measurements and blood parameters are 
shown in Table  1. In  the patients with nodules, statisti-
cally significant increases were observed in IGFB3, blood 
glucose and leptin levels, and decreases were noted for 
GH, BMI, homeostasis model assessment (HOMA), LDL 
and phosphorus (P) levels.
In  this study, the frequencies of the GHR-fl/fl, d3/d3, 
and d3/fl genotypes were 62.5, 29.1, and 8.34%, respec-
tively. There was a strong relationship between gene poly-
morphism status and leptin levels in acromegalic patients 
(Table 2). A marked increase was observed in serum leptin 
levels in patients with the GHR-d3/fl genotype (p < 0.01).
Discussion
Acromegaly is an acquired disorder related to excessive 
production of GH and IGF-1 and characterized by pro-
gressive somatic disfigurement and systemic manifesta-
tions.33 Leptin, a neuroregulatory peptide, is secreted by 
adipose tissue in proportion to adipose content. Because 
GH modulates fat mass, the study was undertaken to in-
vestigate the possible effects of acromegaly on leptin in 
patients with and without thyroid nodules.
The  growth-promoting effects of GH on thyroid fol-
licular cells or a concurrent TSH excess are the conven-
tional hypotheses linking acromegaly to thyrotoxicosis.30 
Current evidence favors a TSH-independent mechanism 
in most cases.34 In addition, G protein abnormalities can 
constitutively activate GH-releasing hormone (GHRH) re-
ceptors leading to acromegaly, as well as cause constitutive 
TSH receptor activation leading to thyrotoxicosis.35 This 
may also be a  possible mechanism underlying the com-
bination of acromegaly and thyroid nodules studied here.
In  this study, serum leptin levels in acromegalic pa-
tients with different GHR genotypes (fl/fl, d3/d3, or d3/fl) 
were examined, and a statistically significant relationship 
between gene polymorphism status and nodule forma-
tion was observed. While no differences were found in 
homozygous fl and d3 patients, a marked predisposition 
for thyroid nodule development was observed in patients 
that were heterozygous (d3/fl). Specifically, patients with 
the GHR-d3/fl genotype exhibited both increased leptin 
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levels and a predisposition to nodule formation. Notably, 
nodules were found in all patients with the GHR-d3/fl 
genotype (Table 2).
GH plays an important role in the regulation of adiposity 
and modulates fat deposition and accumulation via regu-
latory molecules in preadipocytes and adipocytes.36 Some 
authors have reported that GH excess is associated with 
decreased leptin levels and decreased fat mass.37 In con-
trast, the present study found that increased leptin levels 
were associated with decreased GH levels in acromegalic 
patients with thyroid nodules. Lower leptin levels have 
been reported in acromegalic patients.1,38 Different treat-
ments for acromegaly lead to increased leptin levels.39–41 
Collectively, the evidence indicates that leptin secretion is 
reduced in active acromegaly, presumably reflecting re-
duced body fat stores. Restoration of GH secretion is as-
Table 1. Mann Whitney U test results of clinical and laboratory characteristics of acromegalic patients with or without thyroid nodule
Parameters
Acromegalic patient with thyroid 
nodule (n = 17)
Acromegalic patient without 
thyroid nodule (n = 7) U p-value
mean rank sum of ranks mean rank sum of ranks
Age (years) 14.07 201.50 11.85  98.50 48.500 ns
BMI (kg/m2) 14.00 238.00  8.86  62.00 34.000 < 0.05*
Weight (kg) 13.38 227.50 10.36  72.50 44.500 ns
Height (cm) 12.29 209.00 13.00  91.00 56.000 ns
Fasting glucose (mg/dL) 14.41 245.00  7.86  55.00 27.000 < 0.05*
Insulin (µIU/mL) 13.53 203.00 10.00  70.00 42.000 ns
HOMA  13.97 237.50  8.93  62.50 34.500 < 0.05*
GH (ng/L) 11.97 203.50 15.79  96.50 50.500 < 0.05*
IGF1 (ng/L) 12.76 217.00 11.86  83.00 55.000 ns
IGFB3 (µg/L) 11.76 200.00 14.29 100.00 47.000 < 0.05*
Total cholesterol (mg/dL) 13.41 228.00 10.29  72.00 44.000 ns
Triglyceride (mg/dL) 13.35 227.00 10.43  73.00 45.000 ns
LDL (mg/dL) 12.12 206.00 13.43  94.00 53.000 ns
HDL (mg/dL) 12.26 208.50 13.07  91.50 55.000 ns
TSH (µIU/mL) 12.94 220.00 11.43  80.00 52.000 ns
Leptin (ng/mL) 13.24 225.00  9.71  75.00 47.000 < 0.05*
FT3 (pg/mL) 12.15 206.50 13.36  93.50 53.500 ns
FT4 (ng/dL) 11.97 203.50 13.79  96.50 50.500 ns
COR (µg/dL) 13.26 225.50 10.64  74.50 46.000 ns
PRL (ng/mL) 12.88 219.00 11.57  81.00 53.000 ns
CA (mg/dL) 12.29 209.00 13.00  91.00 56.000 ns
P (mg/dL) 13.85 235.50  9.21  64.50 36.500 < 0.05*
ALP (IU/L) 13.16 210.50  9.36  65.50 37.500 ns
Right thyroid lobe (mm) 12.38 210.50 12.79  89.50 57.500 ns
Left thyroid lobe (mm) 13.21 224.50 10.79  75.50 47.500 ns
Isthmus (mm) 10.22 163.50 14.92  89.50 27.000 ns
ns – non-significant, * significant differences between the groups (p < 0.05).
Table 2. GHR gene polymorphisms; leptin, IGF-1, and GH levels; and BMI in acromegalic patients with or without thyroid nodule
Patients n Leptin level BMI IGF-1 GH
fl/fl genotypes with nodule 11  6.44 ± 9.09a 28.70 ± 4.61  740.54 ± 326.89 15.77 ± 11.96
fl/fl genotypes without nodule 4  3.25 ± 4.74a 25.72 ± 2.99  436.50 ± 300.98 9.86 ± 7.07
d3/d3 genotypes with nodule 4  7.57 ± 8.60a 28.60 ± 2.65  393.50 ± 272.94 5.36 ± 3.37
d3/d3 genotypes without nodule 3  4.79 ± 2.80a 26.93 ± 1.66 1045.00 ± 677.62 31.43 ± 25.93
d3/fl genotypes with nodule 2 28.19 ± 3.46b 35.15 ± 0.63  563.00 ± 216.37 4.96 ± 9.19
p-value < 0.01** ns ns ns
** The differences between the means of groups carrying different letters in the same column are statistically significant (p < 0.01), ns – non-significant.
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sociated with an increase in leptin levels, probably due to 
an increase in fat stores.1 Leonhardt et al. reported a sig-
nificant increase in serum leptin levels in a hypothyroid 
patient compared to hyperthyroid and normal controls.42 
Similar results were reported by Yoshida et al.43 Leptin is 
also related to the progression of some tumors, including 
thyroid cancers.18–22,24–27
In the present study, a marked increase in leptin levels 
was observed in acromegalic patients with thyroid nod-
ules compared to those without. These findings indicate 
that the thyroid may have a greater effect on leptin levels 
than the pituitary. The mechanism underlying the link be-
tween leptin and LDL levels is not clear. However, some 
authors have reported that leptin has a pro-oxidant effect. 
Previous reports have described leptin having a  direct 
effect on endothelial cell generation of reactive oxygen 
species that have been shown to play a role in LDL oxi-
dation.44–46 In this study, decreased LDL levels may be re-
lated to higher leptin levels in acromegalic patients with 
thyroid nodules.
GHR polymorphism has been reported in acromegaly,but 
to the best of the authors’ knowledge, this is the first study 
investigating anthropometric measurements, blood pa-
rameters and gene polymorphism in acromegalic patients 
with or without thyroid nodules.32 Although the study in-
cluded only a small group of patients because of the rarity 
of the combination of the 2 conditions and the unusual 
inclusion criteria, the results indicate that thyroid nodules 
are associated with changes in some parameters in acro-
megalic patients. Practitioners need to take these results 
into consideration when treating acromegalic patients. 
At the same time, although the GHR-d3/fl genotype was 
a predisposing factor in acromegalic patients in this study, 
there were no differences in IGF-1 levels in these patients. 
The possible cause of this may be related to other growth 
factors, and higher leptin levels may contribute to thyroid 
nodule development. This is a preliminary result, and fur-
ther studies are needed.
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